Circulating Tumor Nucleic Acids to Monitor Treatment Response in Metastatic Melanoma Patients

Overview

About this study

This project will investigate whether the analysis of nucleic acids circulating in the blood from tumors can allow real-time monitoring of treatment response to targeted therapy and immunotherapy for patients who have stage IV metastatic melanoma.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

Age ≥ 18 years.
No co-morbidities that would not allow standard of care systemic treatment.
Stage IV metastatic melanoma.

Exclusion Criteria:

Individuals < 18 years.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Scottsdale/Phoenix, Ariz. Mayo Clinic principal investigator Mahesh Seetharam, M.D.	Open for enrollment	Contact information: Shane Shannon (480) 574-2761 Shannon.Shane@mayo.edu

Mayo Clinic Location

Status

Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Mahesh Seetharam, M.D.

Open for enrollment

Contact information:

Shane Shannon

(480) 574-2761

Shannon.Shane@mayo.edu

More information

Publications

Publications are currently not available

Clinical Trials